Perrigo Company PLC (PRGO)

11,300
-300(-2.59%)
  • Volume:
    1,749,708
  • Bid/Ask:
    11,300/11,330
  • Day's Range:
    11,270 - 11,410
  • Type:Equity
  • Market:Israel
  • ISIN:IE00BGH1M568
  • S/N:01130699

PRGO Overview

Prev. Close
11,600
Day's Range
11,270-11,410
Revenue
13.8B
Open
11,380
52 wk Range
11,270-16,450
EPS
-
Volume
1,749,708
Market Cap
15.15B
Dividend (Yield)
300.66
(2.59%)
Average Vol. (3m)
170,816
P/E Ratio
-
Beta
-
1-Year Change
-29.2%
Shares Outstanding
133,773,881
Next Earnings Date
Mar 03, 2022
What is your sentiment on Perrigo Company PLC?
or
Market is currently closed. Voting is open during market hours.

  • Perrigo to delist from Tel Aviv Stock Exchange
    • BySeeking Alpha-

    Perrigo Company (PRGO) is trading ~3.7% lower in the pre-market after the company announced the submission of paperwork for voluntary delisting of its ordinary shares from trading...

Perrigo Company PLC Company Profile

Employees
11500

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellSellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • 42.5. buy
    1
    • sell
      1
      • md ayas
        0
        • February 27 Earnings call was terribly executed. The CEO was full of excuses as to why he is clueless on the future of the company. They missed earnings and could not give clear answers as the reasons. They demanded for their investors to wait until May 6 for guidance, as they do not know what they are going to do with the business. They only thing they would say is the product pricing is a headwind that will not end, they want to divest the Rx business but there are no buyers, and that they will continue to fight the tax dispute but can not make any claims about its possible outcome.
          0
          • he is just doing that he was joking around
            0
        • I'll be glad if it goes up to $85. Let's hope it will exceed analysts' expectations and maybe beat by a few cents. Cross your fingers pal!
          1
          • prgo had good Q1 2016 earning why she isnt at 130$ yet?
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.